Sutro Biopharma, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $8.92
- 52-Week Range
- $7.15 – $43.85
- Market Cap
- $141.11M
- P/E (TTM)
- —
- EPS (TTM)
- -12.42
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -37.18%
- Gross Margin
- -184.63%
- Operating Margin
- -254.72%
- Profit Margin
- 0.00%
- Current Ratio
- 2.94
- Debt/Equity
- —
- Total Debt
- $9.70M
- Free Cash Flow
- $-105.75M
- Revenue Growth
- -6.10%
- Earnings Growth
- —
- Enterprise Value
- $8.63M
Market Snapshot
About
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. The company uses its proprietary cell-free protein synthesis platform to create antibody drug conjugates (ADCs) and other targeted oncology treatments. Sutro is advancing multiple product candidates through clinical trials for various cancer types.